Navigation Links
Uroplasty to Highlight Urgent PC System at American Urological Association 2008 Annual Meeting
Date:5/12/2008

MINNEAPOLIS, May 12 /PRNewswire-FirstCall/ -- Uroplasty, Inc. (Amex: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunction, announced today that Kenneth M. Peters, M.D., chair of the Department of Urology at Beaumont Hospital in Royal Oak, Michigan, will present preliminary data from the ongoing OrBIT (Overactive Bladder Innovative Therapy) study of the Urgent(R) PC Neuromodulation System at the American Urological Association's annual meeting. Uroplasty's Urgent PC system and Macroplastique(R) will also be featured in seven presentations by leading urologists at Uroplasty's Booth # 3729. The AUA 2008 Annual Meeting will be held from May 17 to May 22 in Orlando, Florida.

"The annual AUA meeting has always been one of the best opportunities for interacting with our customers, and we are excited to host a prestigious line-up of leading urologists who will address the ease-of-use, safety and efficacy of our Urgent PC system for the treatment of urinary frequency, urinary urgency and urge incontinence, symptoms often associated with overactive bladder, and Macroplastique for the treatment of adult female stress urinary incontinence," said Dave Kaysen, President and Chief Executive Officer of Uroplasty, Inc. "We also eagerly anticipate Dr. Peters' presentation of the OrBIT trial. As the clinical evidence supporting Urgent PC continues to expand, we fully expect that even greater numbers of patients and physicians alike will seek out the Urgent PC technology's patient-friendly, highly effective solution to a large and persistent quality of life issue."

Poster Presentation

In a moderated poster presentation, "A Randomized Multi-Center Study Comparing Percutaneous Tibial Nerve Stimulation (PTNS) with Pharmaceutical Therapy for the Treatment of Overactive Bladder," Kenneth M. Peters, M.D., will present preliminary results from the ongoing OrBIT clinical study of the Urgent PC system as compared to tolterodine LA, the leading pharmaceutical treatment for overactive bladder. The poster session will begin on Tuesday, May 20, 2008 at 1:40 p.m. ET.

Uroplasty Booth Presentations

Throughout the AUA conference, Uroplasty will host seven presentations at its Booth #3729. These include:

-- "Benefits of Urgent PC in Treating Patients with Urinary Symptoms," to

be presented by Elizabeth Bozeman, M.D., on Sunday, May 18 and Monday,

May 19 at 12:15 PM;

-- "Urgent PC and the Patient Refractory to Anticholinergic Drugs," to be

presented by Scott MacDiarmid, M.D., on Sunday, May 18 and Monday,

May 19 at 12:45 PM;

-- "Incorporating Urgent PC into a Community-Based Urology Practice," to

be presented by Judy Siegel, M.D., on Monday, May 19 at 2:15 PM and

Tuesday, May 20 at 12:15 PM;

-- "Macroplastique(R) in the Treatment of Female Stress Urinary

Incontinence," to be presented by Edward Gheiler, M.D., on Monday,

May 19 at 2:45 PM.

About the Urgent PC Neuromodulation System

The Urgent PC neuromodulation system is a proprietary, minimally invasive nerve stimulation device designed for office-based treatment of urge incontinence, urinary urgency and urinary frequency. Application of neuromodulation therapy targets specific nerve tissue and disrupts the signals that lead to these urinary symptoms. Uroplasty sells the Urgent PC system in the United States, Canada and countries recognizing the CE mark. Outside of the United States, the Urgent PC is also indicated for the treatment of fecal incontinence.

About Uroplasty, Inc.

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our primary focus is the commercialization of our Urgent PC system, which we believe is the only FDA-approved non-surgical neurostimulation therapy for the treatment of urinary symptoms often associated with overactive bladder (OAB). We also offer Macroplastique(R) Implants, a urethral bulking agent for the treatment of adult female stress urinary incontinence. Please visit Uroplasty, Inc. at http://www.uroplasty.com.

For Further Information:

Uroplasty, Inc. EVC Group

David Kaysen, President and CEO, or Doug Sherk/Matt Selinger (Investors)

Medi Jiwani, Vice President, CFO, 415.896.6820

and Treasurer, Steve DiMattia/Chris Gale (Media)

952.426.6140 646.201.5445


'/>"/>
SOURCE Uroplasty, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Uroplasty Plans to Double Sales Force During Fiscal 2009
2. Uroplasty, Inc. Reports Presentations of Urgent(R) PC Studies at the 2008 Society of Urologic Nurses and Associates Annual Symposium
3. Uroplasty to Present at ROTH Capital Partners 20th Annual OC Growth Stock Conference
4. Uroplasty Expands Marketing Program for Urology Practices
5. Uroplasty, Inc. Announces Pricing of a Public Offering of Its Common Stock
6. Uroplasty, Inc. Reports Record Sales For Second Fiscal Quarter
7. Uroplasty to Host Second Quarter Conference Call on November 1
8. Uroplasty, Inc. Announces Filing of Registration Statement for Offering of Common Stock
9. Highlights for APAs 116th Annual Convention in Boston, Aug. 14-17
10. Isis Reports Financial Results and Highlights for First Quarter of 2008
11. Preliminary Results from Phase 2 Genzyme Study Highlight Potential of Novel Oral Compound for Gaucher Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... Washington, D.C. (PRWEB) , ... June 25, 2016 ... ... will discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June ... share their work on several important health care topics including advance care planning, ...
(Date:6/25/2016)... Lewisville, TX (PRWEB) , ... June 25, 2016 , ... ... in the United States, named Dr. Sesan Ogunleye, as the Medical Director of its ... be the facility Medical Director of our new Mesquite location,” said Dr. James M. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of ... of the latter, setting the bar too high can result in disappointment, perhaps even ... progress toward their goal. , Research from PsychTests.com reveals that behind ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Marcy was in a crisis. Her son James, ... out at his family verbally and physically. , “When something upset him, he couldn’t control ... use it. He would throw rocks at my other children and say he was going ...
(Date:6/24/2016)... ... ... Comfort Keepers® of San Diego, CA is excited to announce they are ... drive cancer patients to and from their cancer treatments. Comfort Keepers provides quality ... and ongoing independence. Getting to and from medical treatments is one of the ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
(Date:6/24/2016)... ALEXANDRIA, Va. , June 24, 2016 ... a set of recommendations that would allow ... information (HCEI) with entities that make formulary and coverage ... determine the "value" of new medicines. The ... that does not appear on the drug label, a ...
(Date:6/24/2016)... , June 24, 2016 According ... by Type (Standard Pen Needles, Safety Pen Needles), Needle ... GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) - ... This report studies the market for the forecast period ... reach USD 2.81 Billion by 2021 from USD 1.65 ...
Breaking Medicine Technology: